Cargando…

Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial

BACKGROUND: CSL112 is a new formulation of human apolipoprotein A-I (apoA-I) being developed to reduce cardiovascular events following acute coronary syndrome. This phase 2a, randomized, double-blind, multicenter, dose-ranging trial represents the first clinical investigation to assess the safety an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tricoci, Pierluigi, D’Andrea, Denise M, Gurbel, Paul A, Yao, Zhenling, Cuchel, Marina, Winston, Brion, Schott, Robert, Weiss, Robert, Blazing, Michael A, Cannon, Louis, Bailey, Alison, Angiolillo, Dominick J, Gille, Andreas, Shear, Charles L, Wright, Samuel D, Alexander, John H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599471/ https://www.ncbi.nlm.nih.gov/pubmed/26307570 http://dx.doi.org/10.1161/JAHA.115.002171

Ejemplares similares

Clinical Pharmacokinetics and Pharmacodynamics of CSL112
por: Ortega-Paz, Luis, et al.
Publicado: (2023)

Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study
por: Gurbel, Paul A., et al.
Publicado: (2018)

Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A‐I and cholesterol efflux capacity in acute myocardial infarction patients
por: Zheng, Bo, et al.
Publicado: (2020)

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)
por: Michael Gibson, C., et al.
Publicado: (2016)

It’s Time to Reassess the High-Density Lipoprotein (HDL) Hypothesis: CSL112, a Novel Promising Reconstituted HDL Formulation
por: Marsche, Gunther
Publicado: (2015)

CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients
por: Gille, Andreas, et al.
Publicado: (2018)

Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A‐I [Human]) to Enhance Cholesterol Efflux Capacity
por: Gille, Andreas, et al.
Publicado: (2018)

Pharmacokinetics and Safety of CSL112 (Apolipoprotein A‐I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function
por: Tortorici, Michael A., et al.
Publicado: (2018)

Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity
por: Didichenko, Svetlana A., et al.
Publicado: (2016)

Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity
por: Kingwell, Bronwyn A., et al.
Publicado: (2022)

Correction to: Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity
Publicado: (2023)

Fungal CSL transcription factors
por: Převorovský, Martin, et al.
Publicado: (2007)

Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction
por: Korjian, Serge, et al.
Publicado: (2023)

ALICE HMPID Csl photocathode coating station
Publicado: (2003)

Dissipative Continuous Spontaneous Localization (CSL) model
por: Smirne, Andrea, et al.
Publicado: (2015)

Fission Yeast CSL Proteins Function as Transcription Factors
por: Oravcová, Martina, et al.
Publicado: (2013)

Dishevelled limits Notch signalling through inhibition of CSL
por: Collu, Giovanna M., et al.
Publicado: (2012)

Fission Yeast CSL Transcription Factors: Mapping Their Target Genes and Biological Roles
por: Převorovský, Martin, et al.
Publicado: (2015)

Nanobiotechnology applications of reconstituted high density lipoprotein
por: Ryan, Robert O
Publicado: (2010)

Investigating the Effect of a Single Infusion of Reconstituted High-Density Lipoprotein in Patients with Symptomatic Carotid Plaques
por: Nasr, Hosaam, et al.
Publicado: (2015)

Effect of CSL112 (apolipoprotein A‐I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross‐study comparison
por: Zheng, Bo, et al.
Publicado: (2022)

Expression profiling and integrative analysis of the CESA/CSL superfamily in rice
por: Wang, Lingqiang, et al.
Publicado: (2010)

Identification of Novel Targets of CSL-Dependent Notch Signaling in Hematopoiesis
por: Hamidi, Habib, et al.
Publicado: (2011)

Dissecting and Circumventing the Requirement for RAM in CSL-Dependent Notch Signaling
por: Johnson, Scott E., et al.
Publicado: (2012)

A proposal for the experimental detection of CSL induced random walk
por: Bera, Sayantani, et al.
Publicado: (2015)

Instrument Pointer Recognition Scheme Based on Improved CSL Algorithm
por: Liu, Hailong, et al.
Publicado: (2022)

Activation of the Notch Signaling Pathway In Vivo Elicits Changes in CSL Nuclear Dynamics
por: Gomez-Lamarca, Maria J., et al.
Publicado: (2018)

An investigation of reconstituted terlipressin infusion stability for use in hepatorenal syndrome
por: Bui, Thi Ngoc Nhieu, et al.
Publicado: (2020)

Pharmacokinetic–pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients
por: Åstrand, Magnus, et al.
Publicado: (2018)

CSL controls telomere maintenance and genome stability in human dermal fibroblasts
por: Bottoni, Giulia, et al.
Publicado: (2019)

OptIC-Notch reveals mechanism that regulates receptor interactions with CSL
por: Townson, Jonathan M., et al.
Publicado: (2023)

The Role of High Density Lipoproteins in Thrombosis
por: Cuchel, Marina, et al.
Publicado: (2002)

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
por: Vergara-Jimenez, Jennifer, et al.
Publicado: (2010)

Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation
por: Procopio, Maria-Giuseppina, et al.
Publicado: (2015)

OPTHiS Identifies the Molecular Basis of the Direct Interaction between CSL and SMRT Corepressor
por: Kim, Gwang Sik, et al.
Publicado: (2018)

Reconstituted High-Density Lipoprotein Modulates Activation of Human Leukocytes
por: Spirig, Rolf, et al.
Publicado: (2013)

Post-reconstitution Stability of Telavancin with Commonly Used Diluents and Intravenous Infusion Solutions
por: Gu, Zhengtian, et al.
Publicado: (2015)

The new element 112
por: Hofmann, S, et al.
Publicado: (1996)

ABC Transporter CslAB, a Stabilizer of ComCDE Signal in Streptococcus mutans
por: Liu, Tianlei, et al.
Publicado: (2015)

The CSL proteins, versatile transcription factors and context dependent corepressors of the notch signaling pathway
por: Contreras-Cornejo, Humberto, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vbashfsaq3vqsgcggn73c9v7qi